Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00081)
| Name |
Neuroinflammation
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 8C1Z
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Responsed Disease | Neuroinflammation [ICD-11: 8C1Z] | |||
| Responsed Drug | Edaravone | Approved | ||
| Responsed Regulator | Toll-like receptor 4 (TLR4) | Driver | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Fatty acid metabolism | hsa01212 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 |
| Response regulation | Edaravone could significantly reduce A1-42-induced apoptosis of HT22 cells and formation of pro-inflammatory factors TNF-, IL-1 and IL-6, prevent the activation of TLR4/NF-kB /NLRP3 signaling pathway, and inhibit ferroptosis and lipid peroxidation. Taken together, EDA contributes to inhibiting neuroinflammatory injury and ferroptosis in A 1-42-induced HT22 cells, and thus may be a potential candidate for the treatment of AD. | |||